It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mutations in superoxide dismutase 1 gene (SOD1) are linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder predominantly affecting upper and lower motor neurons. The clinical phenotype of ALS shows inter- and intrafamilial heterogeneity. The aim of the study was to analyze the relations between individual SOD1 mutations and the clinical presentation using in silico methods to assess the SOD1 mutations severity. We identified SOD1 causative variants in a group of 915 prospectively tested consecutive Polish ALS patients from a neuromuscular clinical center, performed molecular modeling of mutated SOD1 proteins and in silico analysis of mutation impact on clinical phenotype and survival analysis of associations between mutations and hazard of clinical end-points. Fifteen SOD1 mutations were identified in 21.1% familial and 2.3% sporadic ALS cases. Their effects on SOD1 protein structure and functioning inferred from molecular modeling and in silico analyses correlate well with the clinical data. Molecular modeling results support the hypothesis that folding intermediates rather than mature SOD1 protein give rise to the source of cytotoxic conformations in ALS. Significant associations between type of mutation and clinical end-points were found.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mossakowski Medical Research Institute, Polish Academy of Sciences, Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Warsaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162); Umeå University, Department of Clinical Sciences, Neurosciences, Umeå, Sweden (GRID:grid.12650.30) (ISNI:0000 0001 1034 3451)
2 University of Warsaw, Faculty of Chemistry, Biological and Chemical Research Centre, Warsaw, Poland (GRID:grid.12847.38) (ISNI:0000 0004 1937 1290)
3 Pomeranian Medical University, Department of Biochemistry and Medical Chemistry, Szczecin, Poland (GRID:grid.107950.a) (ISNI:0000 0001 1411 4349)
4 Umeå University, Department of Clinical Sciences, Neurosciences, Umeå, Sweden (GRID:grid.12650.30) (ISNI:0000 0001 1034 3451)
5 Jichi Medical University, Division of Neurology, Department of Internal Medicine, Shimotsuke, Japan (GRID:grid.410804.9) (ISNI:0000000123090000)
6 Mossakowski Medical Research Institute, Polish Academy of Sciences, Laboratory of Neurogenetics, Department of Neurodegenerative Disorders, Warsaw, Poland (GRID:grid.413454.3) (ISNI:0000 0001 1958 0162)
7 Medical University of Warsaw, Department of Neurology, Warsaw, Poland (GRID:grid.13339.3b) (ISNI:0000000113287408); Medical University of Warsaw, Neurodegenerative Diseases Research Group, Warsaw, Poland (GRID:grid.13339.3b) (ISNI:0000000113287408)